1

Neuronal hyperexcitability is a DLK-dependent trigger of HSV-1 reactivation that

can be induced by IL-1

Sean R. Cuddy[1,2#], Austin R. Schinlever[1#], Sara Dochnal[1], Jon Suzich[1], Parijat Kundu[1],

Taylor K. Downs[3], Mina Farah[1], Bimal Desai[3], Chris Boutell[4] and Anna R. Cliffe[1]*

1. Department of Microbiology, Immunology and Cancer Biology, University of

Virginia, Charlottesville, VA, 22908.

2. Neuroscience Graduate Program, University of Virginia, Charlottesville, VA,

22908

3. Department of Pharmacology, University of Virginia, Charlottesville, VA, 22908.

4. MRC-University of Glasgow Centre for Virus Research (CVR), Garscube

Campus, Glasgow, Scotland, United Kingdom

# Denotes equal contribution

* Correspondence to Anna R. Cliffe, cliffe@virginia.edu

<u>Abstract</u>

Herpes Simplex Virus (HSV) establishes a latent infection in neurons and

periodically reactivates to cause disease. The neuronal stimuli that trigger HSV

reactivation have not been fully elucidated. Here we demonstrate that HSV reactivation

can be induced by neuronal hyperexcitability. Neuronal stimulation-induced reactivation

was dependent on voltage-gated ion and hyperpolarization-activated cyclic nucleotide-

gated (HCN) channels, demonstrating that neuronal activity is required for reactivation.

Hyperexcitability-induced reactivation was dependent on the neuronal pathway of

DLK/JNK activation and progressed via an initial wave of viral gene expression that was

independent of histone demethylase activity and linked to histone phosphorylation. IL-

1β induces neuronal hyperexcitability and is released under conditions of stress and

fever; both known triggers of clinical HSV reactivation. IL-1β induced histone

phosphorylation in sympathetic neurons, and importantly HSV reactivation, which was

dependent on DLK and neuronal excitability. Thus, HSV co-opts an innate immune

pathway resulting from IL-1 stimulation of neurons to induce reactivation.

Introduction

Herpes simplex virus-1 (HSV-1) is a ubiquitous human pathogen that is present in approximately 40-90% of the population worldwide[1]. HSV-1 persists for life in the form of a latent infection in neurons, with intermittent episodes of reactivation. Reactivation from a latent infection and subsequent replication of the virus can cause substantial disease including oral and genital ulcers, herpes keratitis, and encephalitis. In addition, multiple studies have linked persistent HSV-1 infection to the progression of Alzheimer's disease[2]. Stimuli in humans that are linked with clinical HSV-1 reactivation include exposure to UV light, psychological stress, fever, and changes in hormone levels[3]. How these triggers result in reactivation of latent HSV-1 infection is not fully understood.

During a latent infection of neurons, there is evidence that the viral genome is assembled into a nucleosomal structure by associating with cellular histone proteins[4]. The viral lytic promoters have modifications that are characteristic of silent heterochromatin (histone H3 di- and tri-methyl lysine 9; H3K9me2/3, and H3K27me3)[5-8], which is thought to maintain long-term silencing of the viral lytic transcripts. Hence, for reactivation to occur, viral lytic gene expression is induced from promoters that are assembled into heterochromatin and in the absence of viral proteins, such as VP16, which are important for lytic gene expression upon *de novo* infection. Reactivation is therefore dependent on host proteins and the activation of cellular signaling pathways[3]. However, the full nature of the stimuli that can act on neurons to trigger reactivation and

the mechanisms by which expression of the lytic genes occurs have not been

elucidated.

One of the best characterized stimuli of HSV reactivation at the cellular level is

nerve-growth factor (NGF) deprivation and subsequent loss of PI3K/AKT activity[9-11].

Previously, we found that activation of the c-Jun N-terminal kinase (JNK) cell stress

response via activation of dual leucine zipper kinase (DLK) was required for reactivation

in response to loss of NGF signaling. In addition, recent work has identified a role for

JNK in HSV reactivation following perturbation of the DNA damage/repair pathways,

which also trigger reactivation via inhibition of AKT activity[12]. DLK is a master regulator

of the neuronal stress response, and its activation can result in cell death, axon pruning,

axon regeneration or axon degeneration depending on the nature of activating

trigger[13,14]. Therefore, it appears that HSV has co-opted this neuronal stress pathway of

JNK activation by DLK to induce reactivation. One key mechanism by which JNK

functions to promote lytic gene expression is via a histone phosphorylation on S10 of

histone H3[15]. JNK-dependent histone phosphorylation occurs on histone H3 that

maintains K9 methylation and is therefore known as a histone methyl/phospho switch,

which permits transcription without the requirement for recruitment of histone

demethylases[16,17]. This initial wave of viral lytic gene expression is known as Phase I,

and also occurs independently of the lytic transactivator VP16. In addition, late gene

expression in Phase I occurs independent of viral genome replication[18,19]. A sub-

population of neurons then progress to full reactivation (also known as Phase II), which

occurs 48-72h post-stimulus and requires both VP16 and histone demethylase activity

[15,20-23]. However, not all models of reactivation appear to go through this bi-phasic

progression to reactivation as axotomy results in more rapid viral gene expression and

dependence on histone demethylase activity for immediate viral gene expression.

The aim of this study was to determine if we could identify novel triggers of HSV

reactivation and determine if they involved a bi-phasic mode of reactivation. We turned

our attention stimuli that cause heightened neuronal activity because hyperstimulation

of cortical neurons following forskolin treatment or potassium chloride mediated

depolarization has previously been found to result in a global histone methyl/phospho

switch[24]. Whether this same methyl/phospho switch occurs in different types of neurons,

including sympathetic neurons, is not known. Although forskolin has previously been

found to induce HSV reactivation,[25-28], the mechanism by which forskolin induces

reactivation is not known. In particular, if it acts via causing increased neuronal activity

and/or as a consequence of activation of alterative cAMP-responsive proteins including

PKA and CREB. Hyperexcitability of neurons is correlated with changes in cellular gene

expression, increased DNA damage[29,30], and epigenetic changes including H3

phosphorylation[24]. However, DLK-mediated activation of JNK has not been linked to

changes in cellular gene expression nor epigenetic changes in response to

hyperexcitability. Using a variety of small molecule inhibitors, we found that forskolin

induced reactivation was dependent on neuronal activity. In support of a role for

neuronal hyperexcitability causing HSV reactivation, independent stimuli known to

cause heightened neuronal activity also induced HSV to undergo reactivation. In

addition, DLK and JNK activity were required for an initiation wave of viral lytic gene

expression, which occurred prior to viral DNA replication and independently of histone

demethylase activity, indicating that hyperstimulation-induced reactivation also is bi-

phasic

We were also keen to determine whether we could identify a physiological

stimulus for HSV reactivation that acts via causing neurons to enter a hyperexcitable

state. IL-1β is released under conditions of psychological stress and fever[31-34]; both

known triggers of clinical HSV reactivation[35-37]. IL-1β has previously been found to

induce heightened neuronal activity[38-40]. However, an intriguing feature of IL-1β

signaling is its ability to have differential effects on different cell types. For example, IL-

1β is involved in the extrinsic immune response to infection via activation of neutrophils

and lymphocytes. In addition, it can act on non-immune cells including fibroblasts to

initiate an antiviral response[41,42], as has previously been described for lytic infection with

HSV-1[41]. Given these differential downstream responses to IL-1β signaling, we were

particularly interested in the effects of IL-1β treatment of latently-infected neurons.

Interestingly, we found that IL-1β was capable of inducing reactivation of HSV from

mature sympathetic neurons. Inhibition of voltage-gated sodium and hyperpolarization

activated cyclic nucleotide gated (HCN) channels impeded reactivation mediated by

both forskolin and IL-1β. Activity of the cell stress protein DLK was also essential for IL-

1β-mediated reactivation. We therefore identify IL-1β as a novel trigger from HSV

reactivation that acts via neuronal hyperexcitability and highlight the central role of JNK

activation by DLK in HSV reactivation.

Results

<u>Increased Intracellular Levels of cAMP Induces Reactivation of HSV from Latent</u>

<u>Infection in Murine Sympathetic Neurons</u>

Both forskolin and cAMP mimetics are known to induce neuronal hyperexcitation

and have previously also been found to trigger HSV reactivation[25-28]. Using a model of

HSV latency in mouse sympathetic neurons isolated from the super-cervical ganglia

(SCG)[15] we investigated whether forskolin treatment induced reactivation in this system

and the potential mechanism resulting in the initial induction of viral lytic gene

expression. Sympathetic SCG neurons were infected with a Us11-GFP tagged HSV-1[43]

at a multiplicity of infection (MOI) of 7.5 PFU/cell in the presence of acyclovir (ACV).

After 6 days the ACV was washed out and the neuronal cultures monitored to ensure

that no GFP-positive neurons were present. Two days later, reactivation was triggered

by addition of forskolin (Figure 1A). As represented in Figure 1B, forskolin can act

either extracellularly on ion channels or intracellularly to activate adenylate cyclase[44-46].

Dideoxy-forskolin (dd-forskolin) is a cell impermeable forskolin analog that can act

directly on voltage gated ion channels but does not activate adenylate cyclase[44,47]. We

found addition of forskolin but not dd-forskolin triggered robust HSV reactivation (Figure

1C). A slight increase in GFP-positive neurons did occur with dd-forskolin treatment

compared to mock (approximately 6.5-fold increase compared to a 130-fold increase for

forskolin). Based on a Tukey's multiple comparison test, this change from mock treated

neurons was not significant (P=0.07), however, a direct comparison between mock and

dd-forskolin using a T-test suggested a significant induction (P=0.03). Therefore, direct

stimulation of ion-channels by dd-forskolin may trigger some reactivation. However,

Figure 1. HSV-1 Reactivation Induced by Adenylate Cyclase Activation is DLK/JNK-Dependent. (A) Schematic of the primary superior sympathetic ganglia-derived model of HSV latency. Reactivation was quantified based on Us11-GFP positive neurons in presence of WAY-150168, which prevents cell-to-cell spread. (B) Schematic of the cellular pathways activated by forskolin treatment. Forskolin can act both intracellularly to activate adenylate cyclase increasing the levels of cAMP or extracellularly on ion channels. (C) HSV reactivation was induced by treatment with forskolin (60μM) but not the cell-impermeable dideoxy-forskolin (60μM). (D) Reactivation could be triggered by the cAMP mimetic 8-Bromo-cAMP (125μM). (E) Forskolin-induced reactivation was blocked by the adenylate cyclase inhibitor SQ22,536 (50μM). Each point represents a single replicate. In D statistical comparisons were made using an unpaired t-test. In C and E statistical comparisons were made using a one-way ANOVA with a Tukey's multiple comparisons test. *<0.05, **P<0.01.

maximal reactivation requires forskolin to be enter neurons. In support of increased

intracellular levels of cAMP in inducing HSV reactivation, treatment of latently-infected

primary neurons with a cAMP mimetic (8-bromo-cAMP) was sufficient to trigger

reactivation (Figure 1D). Furthermore, inhibition of adenylate cyclase activity using

SQ22, 536[48] significantly diminished HSV reactivation (Figure 1E). Therefore, activation

of adenylate cyclase and subsequent increased intracellular levels of cAMP are

required for robust forskolin-mediated reactivation.

<u>DLK and JNK Activity are Required for the Early Phase of Viral Gene Expression in</u>

<u>Response to Forskolin Treatment</u>

We previously found that DLK-mediated JNK activation was essential for Phase I

reactivation following interruption of nerve growth factor signaling[15]. To determine

whether DLK and JNK activation were crucial for reactivation in response to

hyperexcitability, neurons were reactivated with forskolin in the presence of the JNK-

inhibitor SP600125 (Fig. 2A) or the DLK inhibitor GNE-3511[49] (Fig. 2B). Both the JNK-

and DLK-inhibitors prevented forskolin-mediated reactivation based on the number of

GFP-positive neurons at 3-days post-stimulus. These data therefore indicate

hyperexcitability-induced reactivation is dependent on the neuronal stress pathway

mediated by DLK activation of JNK.

Because we previously found that JNK-activation results in a unique wave of viral gene

expression in response to inhibition of nerve-growth factor signaling, we were especially

intrigued to determine whether hyperexcitability triggers a similar wave of JNK-

dependent viral gene expression. The previously described bi-phasic progression to

viral reactivation is characterized by viral DNA replication and production of infectious

virus, occurring around 48-72h post-stimulus[18], but with an earlier wave of lytic gene

expression occurring around 20h post-stimulus. To determine whether forskolin-

mediated reactivation results in a similar kinetics of reactivation, we investigated the

timing of Us11-GFP synthesis, viral DNA replication, production of infectious virus, and

lytic gene induction following forskolin treatment. In response to forskolin treatment,

Us11-GFP synthesis in neurons started to appear around 48h post-reactivation, with

more robust reactivation observed at 72h (Figure 2C). In contrast to forskolin-mediated

reactivation, the number of GFP-positive neurons following superinfection with a

replication competent wild-type virus resulted in a rapid induction of GFP-positive

neurons by 24h post-superinfection (Figure 2C). Therefore, forskolin-triggered

reactivation results in slower synthesis of Us11-GFP than superinfection. In addition,

these data highlight the ability of forskolin to trigger reactivation from only a

subpopulation of latently infected neurons (approximately 1 in every 3.4 neurons

compared to superinfection).

The production of infectious virus also mirrored the data for the detection of

Us11-GFP positive neurons, with a robust increase in viral titers between 24 and 60h

post-stimulus (Figure S1A). An increase in viral genome copy number was also not

detected until 48h post-stimulus, which continued between 48h and 72h (Figure S1B).

The quantification of viral genome copy number was also carried out in presence of

WAY-150138[50], which prevents packaging of the viral genome[51], therefore indicating

Figure 2. Reactivation Triggered by Forskolin Involves a DLK/JNK Dependent Phase I of Viral Gene Expression.

(A) Reactivation was induced by forskolin in the presence of JNK inhibitor SP600125 (20μM). (B) Reactivation was induced by forskolin in the presence of the DLK inhibitor GNE-3511 (4μM). (C) Reactivation was induced by forskolin or superinfection with a wild-type (F strain) HSV-1 (MOI of 10 PFU/cell) and qualified based on Us11-GFP positive neurons (n=3). (D-F) RT-qPCR for viral mRNA transcripts following forskolin treatment of latently infected SCGs. (G-I) RT-qPCR for viral lytic transcripts at 20h post-forskolin treatment and then in presence of the JNK inhibitor SP600125 (20μM) and the DLK inhibitor GNE-3511 (4μM). In D-L each experimental replicative is represented. Statistical comparisons were made using a one-way ANOVA with a Tukey's multiple comparison. *P<0.05, ** P<0.01, ***P<0.001.

Figure S1

<u>Figure S1 Reactivation Triggered by Forskolin Triggers a Wave of Lytic Gene Expression that Precedes DNA Replication and Infectious Virus Production (supplement to Figure 2)</u>
(A) Titers of infectious virus detected from reactivating neurons induced with forskolin (n=4). (B) Quantification of the relative viral genome copy number following forskolin-mediated reactivation based on *gC* copy number normalized to cellular GAPDH and expressed relative to the 0h time-point (n=7). (C-E) RT-qPCR for viral mRNA transcripts following forskolin treatment of latently infected SCGs. In C-E each biological replicate is represented. Statistical comparisons were made using a one-way ANOVA with a Tukey's multiple comparison. *P<0.05, ** P<0.01, ***P<0.001. (C-E).

that DNA replication occurs in reactivating neurons and not as a consequence of cell-to-

cell spread.

Given the observed 48h delay in viral DNA replication and production of

infectious virus, we were interested to determine if there was a Phase I wave of lytic

gene expression that occurred prior to viral DNA replication. We therefore carried out

RT-qPCR to detect representative immediate-early (*ICP27* and *ICP4*), early (*ICP8* and

UL30), and late (*UL48* and *gC*) transcripts between 5- and 20-hours post addition of

forskolin (Figures 2D-F and S1C-E). For all six transcripts, a significant up-regulation of

mRNA occurred at 20h post-treatment, including the true late gene *gC*, whose

expression would usually only be stimulated following viral genome replication in the

context of *de novo* lytic replication. Therefore, this indicates that lytic gene expression is

induced prior to viral DNA replication and that neuronal hyperexcitability does trigger a

Phase I wave of lytic gene expression. Notably, we did detect small but reproducible

induction of *ICP27* mRNA at 5h post-stimulus, followed by a second induction at 20h

(Figure 2D), indicating that there is likely differential regulation of some viral lytic

transcripts during Phase I reactivation induced by hyperexcitability that is distinct from

both NGF-deprivation and *de novo* lytic infection.

To determine whether JNK and DLK were required Phase I gene expression in

response to hyperexcitability, we investigated viral mRNA levels following forskolin-

mediated reactivation in the presence of the JNK inhibitor SP600125. We found a

significant reduction in *ICP27* (2.2-fold), *UL30* (3.3-fold) and *gC* (5.5-fold) mRNA levels

at 20h post-stimulus in the presence of SP600125 (Figure 2G-I). For all genes tested,

there was no significant increase in mRNAs in the JNK-inhibitor treated neurons

compared to mock. We observed comparable results following treatment with the DLK

inhibitor GNE-3511, with a 2.3-, 3-, 8.8-fold decrease in *ICP27*, *UL30* and *gC* mRNAs

respectively compared to forskolin treatment alone, and no significant increase in

mRNA levels compared to the reactivated samples (Figure 2G-I).

It is possible that in addition to JNK, other signal transduction proteins are

important in forskolin-mediated reactivation. Previous data has found that DLK can be

activated by PKA, which is known to be activated by cAMP[52]. However, using well

characterized inhibitors of PKA, along with the PKA-activated transcription factors

CREB, in addition to two other cAMP responsive proteins Rapgef2 and EPAC, we did

not find that these cAMP activated proteins were required for Phase I reactivation

(Figure S2). Inhibition of PKA or CREB did reduce Phase II reactivation (Figure S2A

and C) but had no effect on Phase I (Figure S2B and D, P=0.354 forskolin versus

forskolin + KT 5720, P=0.963 forskolin vs. forskolin + 666-15, Tukey's multiple

comparison test). Inhibition of Rapgef2 or EPAC had no effect on HSV reactivation

(Figure S2E and F). Taken together, these data suggest that it is hyperexcitability

induced by forskolin that induces a Phase I wave of gene expression via activation of

DLK and JNK.

Figure S2

Figure S2. Effect of PKA, CREB, Rapgef2 and EPAC Inhibition on HSV-1 Reactivation. (A) Latently infected cultures were reactivated with forskolin (60 μM) in the presence of the PKA inhibitor KT 5720 (3 μM) and the number of Us11-GFP positive neurons quantified at 3 days post-reactivation. (B) RT-qPCR for the viral lytic transcript ICP27 at 20h post-forskolin treatment and in the presence of KT 5720. (C) Latently infected cultures were reactivated with forskolin in the presence of the CREB inhibitor 666-15 (2 μM). (D) RT-qPCR for ICP27 at 20h post-forskolin treatment and in the presence of 666-15. (E) Latently infected cultures were reactivated with forskolin (60μM) in the presence of the EPAC inhibitor ESI09 (10 μM). (F) Latently infected cultures were reactivated with 8-Bromo-cAMP (125μM) in the presence of the Rapgef2 inhibitor SQ22,536 (50 μM). Individual experimental replicates are represented. Statistical comparisons were made using a one-way ANOVA with a Tukey's multiple comparison. *P<0.05, ** P<0.01, ***P<0.001.

<u>Forskolin Triggers a Phase I Wave of Viral Gene Expression that is Independent of</u>

<u>Histone Demethylase Activity.</u>

Hyperexcitability results in the propensity of neurons to fire repeated action

potentials, and is associated with specific changes in histone posttranslational

modifications. The first is physiological DNA damage[29,30], measured by the intensity of

γH2AX staining in neuronal nuclei. Forskolin treatment was associated with an increase

in the levels of γH2AX at 5h post-treatment, which resolved by 15h post-treatment

(Figure S3A and C), and is therefore indicative of physiological DNA damage and

repair, which occurs upon neuronal hyperexcitability. A second reason for probing the

DNA damage/repair pathway in response to forskolin treatment is that previously

reactivation of HSV from latency has been associated with perturbation of the DNA

damage/repair response[12]. In this previous study, both inhibition of repair and

exogenous DNA damage resulted in loss of AKT phosphorylation by PHLPP1, which

was required for HSV reactivation. Although we did observe increased levels of γH2AX

following forskolin treatment, this was not accompanied by a loss of pAKT measured at

15h post-treatment (Figure S3D). This indicates that HSV reactivation in response to

forskolin treatment does not involve dephosphorylation of AKT. Therefore,

hyperexcitability triggers reactivation via an alternative mechanism that does not feed

into AKT phosphorylation.

Previously, we found that Phase I reactivation is accompanied with a JNK-

dependent histone methyl/phospho (marked by H3K9me3/pS10) switch on lytic

promoters[15]. In cortical neurons, one study has found that hyperexcitability results in

increased H3K9me3/pS10[24]. Therefore, we were particularly interested to determine

whether forskolin treatment of sympathetic neurons triggered a histone S10

phosphorylation on H3K9me3. Forskolin triggered a transient increase in

H3K9me3/S10p at 5h post-treatment that had returned to baseline by 10h (Figure S3A

and B). This indicates that, in keeping with cortical neurons, forskolin induces a histone

H3K9me3/pS10 methyl/phospho switch on regions on cellular chromatin.

We next sought to determine whether the phospho/methyl switch that arises as a

result of hyperexcitability plays a role in Phase I of HSV reactivation. We therefore

investigated whether viral genomes were co-localized with H3K9me3/S10p following

forskolin treatment. To visualize HSV genomes, viral stocks were grown in the presence

of EdC as described previously[53,54]. Click-chemistry was performed on latently infected

and neurons following forskolin treatment. As shown in Figure 3A and B, viral genomes

co-localized with H3K9me3/pS10 following robust H3K9me3/S10p staining at 5h. The

percentage of viral genomes that co-localized with H3K9me3/S10p was significantly

increased compared to the mock reactivated samples at 5h and 20h post-forskolin

treatment (Figure 3A).

Serine phosphorylation adjacent to a repressive lysine modification is thought to permit

transcription without the removal of the methyl group[17,24]. Therefore, we investigated

whether histone demethylase activity was required for the initial induction in lytic gene

expression following forskolin treatment. Previously, the H3K9me2 histone demethylase

LSD1 has been found to be required for full HSV reactivation[20,23], and in our *in vitro*

Figure 3

Figure 3. The Initial Wave of Viral Lytic Gene Expression During Forskolin-mediated Reactivation is Independent on Histone Demethylase Activity. (A) Quantification of the percentage of genome foci stained using click-chemistry that co-localize with H3K9me3/S10p. At least 15 fields of view were blindly scored from two independent experiments. Whiskers represent the 2.5-97.5 percentile range. (B) Representative images of click-chemistry based staining of HSV-EdC genomes and H3K9me3/S10p staining at 5h post-forskolin treatment. (C and D). Effect of the LSD1 inhibitors OG-L002 and S 2101 on forskolin-mediated Phase I of reactivation determined by RT-qPCR for *ICP27* (C) and *gC* (D) viral lytic transcripts at 20h post-forskolin treatment and in the presence of 15μM OG-L002 and 20μM S 2102. (E) Effect of the JMJD3 and UTX inhibitor GSK-J4 (2μM) on forskolin-mediated Phase I measured by RT-qPCR for viral lytic transcripts ICP27 (E) and gC (F) at 20h post-forskolin treatment and in the presence of GSK-J4. For C-F each experimental replicate is represented. (C-F). Statistical comparisons were made using a one-way ANOVA with a Tukey's multiple comparison. *P<0.05, ** P<0.01, ***P<0.001.

Figure S3

Figure S3. Forskolin Treatment Induces Hyperexcitability-associated Histone Post-translational Modification in Sympathetic Neurons. SCG neurons were treated with forskolin and immunofluorescence staining was carried out for H3K9me3/S10p, the DNA damage marker γH2AX and the neuronal marker beta III-tubulin. (B) Quantification of neuronal nuclear staining intensity for H3K9me3 (>150 cells/condition). (C) Quantification of neuronal nuclear staining for γH2AX. In B and C, whiskers represent the 2.5-97.5 percentile range. (D). Western blotting for pS475-AKT, total AKT, pS73-c-Jun and tubulin at 15h post-treatment with the PI3-kinase inhibitor LY294002 (20μM) or forskolin (60 μM). (E) Effect of the LSD1 inhibitors OG-L002 (15μM) and S 2101 (20μM) on forskolin-mediated reactivation measured by Us11-GFP positive neurons. (F) Effect of the JMJD3 and UTX inhibitor GSK-J4 (2μM) on forskolin-mediated reactivation measured by Us11-GFP positive neurons. Statistical comparisons were made using a one-way ANOVA with a Tukey's multiple comparison. *P<0.05, ** P<0.01, ***P<0.001 (E, F).

model this was determined by the synthesis of late viral protein at 48-72h post-

reactivation[15]. Addition of two independent LSD1 inhibitors (OG-L002 and S 2102)

inhibited Us11-GFP synthesis at 72h post-reactivation (Figure S3E). Hence, LSD1

activity, and presumably removal of H3K9-methylation is required for forskolin-mediated

reactivation. However, LSD1 inhibition did not prevent the initial induction of *ICP27* and

*g*C mRNA expression at 20h post-forskolin treatment (Figure 3C and D). Therefore, this

initial wave of viral lytic gene expression following forskolin-mediated reactivation is

independent of histone H3K9 demethylase activity.

We previously found that H3K27me demethylase activity is required for full reactivation

but not the initial wave of gene expression[15]. However, because of the lack of an

antibody that specifically recognizes H3K27me3/S28p and not also H3K9me3/S10p[15],

we are unable at this point to investigate genome co-localization with this combination

of modifications. However, we could investigate the role of the H3K27me demethylases

in forskolin-mediated reactivation. Treatment of neurons with the UTX/JMJD3 inhibitor

GSK-J4[55] prevented the synthesis of Us11-GFP at 72h post-reactivation, indicating that

removal of K27 methylation is required full reactivation (Figure S3F). However, the initial

burst of gene expression (assessed by *ICP27* and *g*C mRNA levels) was robustly

induced at 20h post-forskolin treatment in the presence of GSK-J4 (Figure 3E and F).

Taken together, our data indicate that the initial phase of gene expression following

forskolin treatment is independent of histone demethylase activity and therefore

consistent with a role for a histone methyl/phospho switch in permitting lytic gene

expression.

Forskolin-Mediated Reactivation Requires Neuronal Excitability

Given that the HSV genome co-localized with regions of hyperexcitability-induced

changes in histone phosphorylation, we investigated whether reactivation was linked to

neuronal excitability. To inhibit action potential firing, we treated neurons with

tetrodotoxin (TTX), which inhibits the majority of the voltage-gated sodium channels and

therefore depolarization. Addition of TTX significantly inhibited HSV reactivation

triggered by forskolin, as measured by Us11-GFP positive neurons at 72 hours post-

stimulus (Figure 4A). To further confirm a role for repeated action potential firing in

forskolin-mediated reactivation, we investigated the role of voltage-gated potassium

channels, which are required for membrane repolarization. Addition of TEA, which

inhibits voltage-gated potassium channel activity, also blocked HSV reactivation

measured by Us11-GFP positive neurons at 3 days post-forskolin treatment (Figure 4B).

Taken together, these data indicate that action potential firing is required for forskolin-

mediated reactivation.

Increased levels of cAMP can act on nucleotide-gated ion channels, including the

hyperpolarization-activated cyclic nucleotide gated (HCN) channels. HCN channels are

K^+ and Na^+ channels that are activated by membrane hyperpolarization[56,57]. In the

presence of high levels of cAMP, the gating potential of HCN channels is shifted in the

positive direction, such that HCN channels can open at resting membrane potential,

resulting in an increased propensity of neurons to undergo repeated firing[57-59]. HCN

channel activity can be blocked by ZD 7288, Ivabradine, or cesium chloride. Addition of

ZD 7288 (Figure 4C), Ivabradine (Figure S4A) or CsCl (Figure S4B) all significantly

Figure 4

<u>Figure 4. HSV Reactivation Mediated by Forskolin Requires Neuronal Excitability.</u>
(A) Latently infected cultures were reactivated with forskolin in the presence of the voltage-gated sodium channel blocker tetrodotoxin (TTX; 1μM) and the number of Us11-GFP positive neurons quantified at 3 days post-reactivation. (B) Latently infected cultures were reactivated with forskolin in the presence of the voltage-gated potassium channel blocker tetraethylammonium (TEA; 10 mM) and the number of Us11-GFP positive neurons quantified at 3 days post-reactivation. (C) Forskolin-mediated reactivation in the presence of the HCN channel blockers ZD 7288 (10μM) quantified as the numbers of Us11-GFP positive neurons at 3 days post-reactivation. (D) The effect of ZD 7288 on the HSV lytic gene transcript ICP27 during Phase I reactivation measured at 20h post-forskolin treatment by RT-qPCR. Individual experimental replicates are represented. (E and F) Quantification of the relative nuclear staining for H3K9me3/S10p and γH2AX in SCG neurons at 5h post-forskolin treatment and in the presence of ZD 7288 from two independent experiments. Statistical comparisons were made using a one-

way ANOVA with a Tukey's multiple comparison (A-D) or two-tailed unpaired t-test (E-F).
*P<0.05, ** P<0.01, ***P<0.001.

Figure S4

Figure S4. HSV Reactivation Mediated by Forskolin Requires Neuronal Excitability. (A and B) Latently infected cultures were reactivated with forskolin in the presence of the HCN channel inhibitors ivabradine (20µM; A) and CsCl (3mM; B). Latently infected cultures were reactivated with forskolin in the presence of the HCN inhibitor ZD 7288 (10 µM) and viral lytic transcripts measured at 20h post-reactivation (C and D). Individual experimental replicates are represented. Statistical comparisons were made using a one-way ANOVA with a Tukey's multiple comparison. *P<0.05, ** P<0.01.

reduced HSV reactivation triggered by forskolin, as measured by Us-11 GFP positive

neurons at 3 days post-stimulus. To determine whether HCN channel activity was

required for the initial induction of HSV lytic mRNA expression, we assessed viral

mRNA expression during Phase I in the presence and absence of ZD 7288. Expression

of representative lytic mRNAs *ICP27* (Figure 4D), *UL30* and *gC* (Figure S4C and D)

were significantly decreased in the presence of ZD 7288 compared to the forskolin

treated neurons alone, and were not significantly increased compared to the mock

treated samples. Therefore, HCN channel activity is required for the initial induction of

lytic gene expression during Phase I reactivation mediated by forskolin.

We also confirmed that inhibition of HCN-channel activity affected the levels of

hyperexcitability-associated changes in histone post-translational modifications.

Addition of ZD 7288 resulted in significantly decreased staining intensities of both

H3K9me3/S10p and γH2AX at 5h post-forskolin treatment (Figure 4E and 4F), which

was the peak time-point for which we observed these changes upon forskolin treatment

alone (Figure S3B and S3C). Therefore, activity of the HCN channels in response to

increased levels of cAMP, results in hyperexcitability-associated changes in histone

modifications and reactivation of HSV from latent infection.

HSV Reactivation can be Induced by Stimuli that Directly Increase Neuronal Excitability

The role of ion-channel activity in forskolin-mediated reactivation prompted us to

investigate whether additional stimuli that induce hyperexcitability in neurons also

trigger HSV reactivation. We were also interested in whether reactivation required

Figure 5

Figure 5. HSV Reactivation Triggered by Prolonged Neuronal Hyperexcitability is DLK/JNK Dependent. (A) Latently infected SCG cultures were treated with forskolin or KCl (55mM) for the indicated times followed by wash-out. Reactivation was quantified by number of Us11-GFP positive neurons at 3 days after the initial stimulus was added. (B) Latently infected neurons were placed in tetrodotoxin (TTX; 1μM) for 2 days and the TTX was then washed out. At the time of wash-out the JNK inhibitor SP600125 (20μM) or DLK inhibitor GNE-3511 (4μM) was added. Reactivation was quantified at 3-days post-wash-out. Individual experimental replicates are represented. Statistical comparisons were made using a one-way ANOVA with a Tukey's multiple comparison. **P<0.01, *** P<0.001.

chronic versus short term hyperexcitability. Increasing the extracellular concentration of

KCl is well-known to induce action potential firing. Therefore, we investigate the timing

of both KCl and forskolin-mediated hyperexcitability in HSV reactivation. Both of these

treatments triggered HSV reactivation more robustly if applied for 8h or more (Figure

5A). This indicates that chronic neuronal hyperexcitability is important in inducing

reactivation of HSV.

To further clarify that hyperexcitability can directly trigger HSV reactivation, we

investigated the effects of removal from a TTX block on latently infected neurons.

Addition of TTX to neurons results in synaptic scaling, so that when the TTX is removed

the neurons enter a hyperexcitable state[60-63]. TTX was added to the neurons for 2 days

and then washed out. This resulted in a robust HSV reactivation as determined by

Us11-GFP synthesis (Figure 5B). We also investigated whether the JNK-cell stress

pathway was important in HSV reactivation in response to TTX-release. Addition of the

JNK inhibitor SP600125 or the DLK inhibitor GNE-3511 blocked HSV reactivation

following TTX-release. Therefore, directly inducing neuronal hyperexcitability triggers

HSV reactivation in a DLK/JNK-dependent manner.

IL-1β Triggers HSV Reactivation in Mature Neurons in a DLK and HCN Channel-

Dependent Manner

Our data thus far point to a reactivation of HSV following increasing episodes of

neuronal hyperexcitability in a way that requires activation of the JNK-cell stress

pathway. However, we wished to link this response to a physiological trigger that may

stimulate HSV reactivation *in vivo*. Increased HCN-channel activity has been associated

with inflammatory pain resulting from the activity of pyrogenic cytokines on neurons[64]. In

addition, IL-1β is known to act on certain neurons to induce neuronal excitation[38-40]. IL-

1β is released in the body during times of chronic, psychological stress. In addition, IL-

1β contributes to the fever response[31-34]. In sympathetic neurons, we found that

exposure of mature neurons to IL-1β induced an accumulation of the hyperexcitability-

associated histone post-translational modifications γH2AX and H3K9me3/S10p (Figure

6A-C). We did not observe the same changes for post-natal neurons. The reasons for

this maturation-dependent phenotype are unknown at this point but we hypothesize it

could be due to changes in the expression of cellular factors required to respond to IL-

1β. Therefore, these experiments were carried out on neurons that were postnatal day

28. The kinetics of induction of these histone modifications was different from what we

had previously observed for forskolin treatment, as both γH2AX and H3K9me3/S10p

steadily accumulated to 20h post-treatment. This likely reflects the activation of

upstream signaling pathways in response to IL-1β prior to inducing

neuronal excitation as IL-1β is known to increase the expression of voltage-gated

sodium channels[40]. Importantly, IL-1β was able to trigger HSV reactivation in mature

neurons (Figure 6D). Inhibition of voltage-gated sodium channels by TTX resulted in a

significant decrease in the ability of IL-1β to induce reactivation (Figure 6E), therefore

indicating that IL-1β triggered reactivation is via increasing neuronal activity.

Reactivation was reduced in the presence of the HCN-channel inhibitor ZD 7288,

although this decrease was not significant (P=0.2255), perhaps suggesting that IL-1β

Figure 6

Figure 6. IL-1β-Induced HSV Reactivation is Linked to Heightened Neuronal Excitability and DLK Activation. (A) Adult P28 SCG neurons were treated with IL-1β (30ng/mL) for 15 hrs and stained for H3K9me3/S10p, γH2AX and beta II-tubulin to mark neurons. (B-C) Quantification of the intensity of H3K9me3/S10p and γH2AX in neuronal nuclei following forskolin treatment from two independent experiments. (D). Addition of IL-1β to latently infected cultures of mature SCG neurons triggers HSV reactivation. (E). Quantification of IL-1β induced reactivation in the presence of the voltage gated sodium channel blocker TTX (1μM), the HCN channel blocker ZD 7288 (10μM) and the DLK inhibitor GNE-3511 (4μM). In D and E individual experimental replicates are represented. Statistical comparisons were made using or two-tailed unpaired t-test (D) or a one-way ANOVA with a Tukey's multiple comparison (B,C & E). *P<0.05, **P<0.01, *** P<0.001.

induction of neuronal activity is not directly due to the action of cAMP on HCN channels

and instead HCN-channel activity may be required for maximal hyperexcitability and

reactivation. Importantly, addition of the DLK inhibitor GNE-3511 blocked reactivation in

response to IL-1β (Figure 6E). Therefore, IL-1β can induce HSV reactivation that is both

dependent on neuronal activity and induction of the JNK neuronal cell stress response.

<u>Discussion</u>

As herpesviruses hide in the form of a latent infection of specific cell types, they

sense changes to the infected cell, resulting in the expression of viral lytic genes and

ultimately reactivation. HSV establishes latency in neurons and has previously been

found to respond to activation of a neuronal stress signaling pathway[15]. As an excitable

cell type, the function of neurons is to rapidly transmit stimuli via the firing of action

potentials, and under conditions of hyperexcitability, neurons increase their propensity

to fire repeated action potentials. Here we show that this state of hyperexcitability

induces HSV to undergo reactivation in a DLK/JNK dependent manner, indicating that

the virus responds to both activation of cell stress signaling and prolonged

hyperexcitability via a common pathway to result in reactivation. This common pathway

also permits viral lytic gene expression from silenced promoters without the requirement

of histone demethylase activity via a histone methyl/phospho switch. Conditions that

result in hyperexcitability include prolonged periods of stress and inflammation, which

are both linked to the release of IL-1β[31-34]. Consistent with this, here we show that IL-1β

induces DNA damage and histone H3 phosphorylation in sympathetic neurons, which

are both markers of neuronal excitability. Importantly, IL-1β triggered HSV reactivation

that was dependent on neuronal activity and activation of DLK. Therefore, this study

identifies a physiological stimulus that induces HSV reactivation via increasing neuronal

excitability and places DLK/JNK signaling and a histone phospho/methyl switch as

central to HSV reactivation.

Experiments using primary neuronal *in vitro* model systems and inducing

reactivation by PI3-kinase inhibition have shown that reactivation progresses over two

phases. Phase I involves the synchronous up-regulation of lytic gene expression that

occurs independently of the viral transactivator VP16 and the activity of cellular histone

demethylases[15,18]. A population of neurons progress to full reactivation (Phase II), which

is dependent on both VP16 and HDM activity[15,18]. We previously found that lytic gene

expression in Phase I is DLK/JNK dependent and is corelated with a JNK-dependent

histone methyl/phospho switch on lytic gene promoters[15]. Here we demonstrate that a

Phase I wave of viral gene expression that is dependent on activation of JNK but not

histone demethylases also occurs in response to neuronal hyperexcitability. The co-

localization of viral genomes with H3K9me3/pS10 indicates that a histone

methyl/phospho switch also permits lytic gene expression to occur following forskolin

treatment in a manner that is independent of HDM activity. This indicates that

reactivation proceeds via a Phase I-wave of gene expression in response to multiple

different stimuli. However, we note that there may be differences in the mechanism and

kinetics of reactivation with different stimuli and/or strains of HSV-1 as reactivation

triggered by axotomy may bypass Phase I[19,20] and reactivation induced *in vivo* by heat

shock with a more pathogenic strain of HSV triggered more rapid reactivation[65]. It will be

especially interesting to determine in the future whether there are differences in the

progression to reactivation with different strains of HSV. Ultimately, these reactivation

kinetics may relate differences in the epigenetic structures of viral genomes that vary

based on virus strains or differential manipulation of host-cell signaling pathways.

The Wilcox lab demonstrated in 1992 that reactivation can be induced by

forskolin, and it has since been used as a trigger in multiple studies[25-28]. However, the

mechanism by which increasing levels of cAMP induces lytic gene expression was not

known. Here we link cAMP-induced reactivation to the excitation state of the neuron and

show that the initial induction of viral gene expression is dependent on DLK and JNK

activity but independent of CREB and PKA. The activity of PKA may be required for full

reactivation, which is also consistent with a role for PKA in overcoming repression of the

related Pseudorabies Virus during *de novo* axonal infection[66]. Our data also suggest

that CREB may be involved in the progression to full reactivation. However, the

mechanism of action of the inhibitor used here, 666-15, is not entirely clear. It has been

reported as preventing CREB-mediated gene expression, but may act to prevent

recruitment of histone acetyltransferases[67]. Therefore, inhibition of Phase II reactivation

by 666-15 would be consistent with more large-scale chromatin remodeling on the viral

genome at this stage. In addition, previous work has identified a role for inducible cAMP

early repressor (ICER) in HSV reactivation[26]. ICER is a repressor of gene expression

that acts via heterodimerization with members of the CREB/ATF family of transcription

factors. CREB expression is also down-regulated by loss of NGF-signaling[68], a known

trigger of HSV reactivation. Therefore, it is conceivable that inhibition, rather than

activation, of CREB is important for reactivation of HSV from latency.

Neuronal hyperexcitability results in DNA damage followed by repair, which

together are thought to mediate the expression of cellular immediate early genes[29,30].

Here we show that forskolin treatment and IL-1β also induce DNA damage in

sympathetic neurons. Previously, HSV reactivation has been found to occur following

inhibition of DNA damage, inhibition of repair, and exogenous DNA damage[12]. In the

context of repair inhibition or exogenous DNA damage, reactivation was dependent on

dephosphorylation of AKT by the PHLPP1 phosphatase and activation of JNK, and

therefore feeds into the same pathway as PI3K-inhibition. However, we did not observe

decreased AKT phosphorylation in response to forskolin treatment, indicating that the

mechanism of reactivation is distinct following physiological levels of DNA damage

resulting from neuronal hyperexcitability versus perturbation of the damage/repair

pathways.

Conditions that result in hyperexcitability include prolonged periods of stress and

inflammation, which are both linked to the release of IL-1β[31-34]. Consistent with these

findings, we show that IL-1β treatment induces two markers of neuronal excitability,

DNA damage and histone H3 phosphorylation, in primary sympathetic neurons. The IL-

1 family of cytokines act via the IL-1 receptor to activate downstream signaling

pathways [69]. IL-1β is released systemically during prolonged periods of psychological

stress and upon infection via activation of the inflammasome[31-34]. IL-1α, which also

signals via the IL-1R, is released locally as an alarmin. Interesting IL-1α and IL-1β are

found at high levels in keratinocytes and are released upon HSV-1 infection[41], where

they can mediate antiviral responses in underlying stromal fibroblasts and endothelial

cells. Antiviral responses mediated by IL-1 signaling have been found to involve NF-κB,

IRF3 and/or IRF1[42]. The downstream signaling elicited by IL-1 in neurons has not been

clearly defined and likely varies between different subtypes of neurons. NF-κB has been

reported to be absent in certain subtypes of neurons but constitutively active in

others[70,71], and a recent study suggests that NF-κB levels increase with neuronal

maturation[72], which may be why we only observed IL-1-mediated reactivation in mature

neurons. Additional studies have found a role for p38MAPK signaling and AKT/mTOR

signaling in neuronal IL-1-mediated responses[73,74]. A common feature of IL-1 signaling

in neurons is increased excitability, which has been associated with neurotransmitter

release, and mediates a variety of physiological responses including behavior

modulation and an intersection with the hosts' immune response[38-40]. IL-1 is also

associated with pathological conditions, including neurodegenerative disease such as

Alzheimer's disease[75]. There are multiple studies linking HSV-1 infection to the

progression of Alzheimer's[2]; therefore, the combination of both HSV infection and

increased IL-1 could have a feed forward effect on the progression of Alzheimer's

disease by promoting increased reactivation of HSV from latency.

Previously, we found that JNK activation by DLK is required for reactivation

following interruption of the NGF-signaling pathway. Here we find that forskolin and IL-

1β-mediated reactivation also required DLK activity, further reinforcing the central role of

DLK and JNK in reactivation of HSV from latency. DLK is known as a master regulator

of neuronal response to stress stimuli and mediates whole cell death, axon pruning,

regeneration or generation depending on the nature of the stimuli. However, it has not

before been linked to neuronal hyperexcitability or the response to IL-1β signaling. The

known mechanisms of DLK activation include loss of AKT activation and

phosphorylation by PKA[52,76], neither of which could be linked to HSV reactivation

mediated by forskolin in this study. Following activation by DLK, one mechanism by

which JNK is thought to permit lytic gene expression is via recruitment to viral promoters

and histone phosphorylation. However, it is likely that there are additional, JNK-

dependent effects including activation of pioneer or transcription factors that also

mediate viral gene expression. Further insight into how HSV has hijacked this cellular

pathway to induce lytic gene expression may lead to novel therapeutics that prevent

reactivation, in addition to providing information on how viral gene expression initiates

from promoters assembled into heterochromatin.

Acknowledgements

We thank Ian Mohr (NYU) for supplying the Us11-GFP virus used in this study. This

work was supported by NIH/NINDS R01NS105630 (to A.R.C), NIH/NIAID T32AI007046

(S.R.C. and J.B.S), NIH/NEI F30EY030397 (J.B.S), NIH/NIGMS T32GM008136 (S.D)

and T32GM007267 (J.B.S) and MRC (https://mrc.ukri.org) MC_UU_12014/5 (C.B).

Materials and Methods

Reagents

Compounds used in the study are as follows: Acycloguanosine, FUDR, Uridine,

SP600125, GNE-3511, GSK-J4, L-Glutamic Acid, and Ivabradine (Millipore Sigma);

Forskolin, LY 294002, 666-15, SQ 22536, KT 5720, Tetraethylammonium chloride,

Cesium chloride, OG-L002, S2101, Tetrotdotoxin, and ESI-09 (Tocris); 1,9-dideoxy

Forskolin, ZD 7288 and 8-bromo-cyclic AMP (Cayman Chemicals); Nerve Growth

Factor 2.5S (Alomone Labs); Primocin (Invivogen); Aphidicolin (AG Scientific); IL-1β

(Shenandoah Biotechnology); WAY-150138 was kindly provided by Pfizer, Dr. Jay

Brown and Dr. Dan Engel at the University of Virginia, and Dr. Lynn Enquist at

Princeton University. Compound information and concentrations used can be found

below in Table S1. Compound concentrations were used based on previously published

IC50s and assessed for neuronal toxicity using the cell body and axon health and

degeneration index (Table S5 and S6). All compounds used had an average score $\leq$1.

Preparation of HSV-1 Virus Stocks

HSV-1 stocks of eGFP-Us11 Patton were grown and titrated on Vero cells obtained

from the American Type Culture Collection (Manassas, VA). Cells were maintained in

Dulbecco's Modified Eagle's Medium (Gibco) supplemented with 10% FetalPlex

(Gemini Bio-Products) and 2 mM L-Glutamine. eGFP-Us11 Patton (HSV-1 Patton strain

with eGFP reporter protein fused to true late protein Us11[43]) was kindly provided by Dr.

Ian Mohr at New York University.

Primary Neuronal Cultures

Sympathetic neurons from the Superior Cervical Ganglia (SCG) of post-natal day 0-2

(P0-P2) or adult (P21-P24) CD1 Mice (Charles River Laboratories) were dissected as

previously described[15]. Rodent handling and husbandry were carried out under animal

protocols approved by the Animal Care and Use Committee of the University of Virginia

(UVA). Ganglia were briefly kept in Leibovitz's L-15 media with 2.05 mM L-Glutamine

before dissociation in Collagenase Type IV (1 mg/mL) followed by Trypsin (2.5 mg/mL)

for 20 minutes each at 37 °C. Dissociated ganglia were triturated, and approximately

10,000 neurons per well were plated onto rat tail collagen in a 24-well plate.

Sympathetic neurons were maintained in CM1 (Neurobasal® Medium supplemented

with PRIME-XV IS21 Neuronal Supplement (Irvine Scientific), 50 ng/mL Mouse NGF

2.5S, 2 mM L-Glutamine, and Primocin). Aphidicolin (3.3 µg/mL), Fluorodeoxyuridine

(20 µM) and Uridine (20 µM) were added to the CM1 for the first five days post-

dissection to select against proliferating cells.

Establishment and Reactivation of Latent HSV-1 Infection in Primary Neurons

Latent HSV-1 infection was established in P6-8 sympathetic neurons from SCGs.

Neurons were cultured for at least 24 hours without antimitotic agents prior to infection.

The cultures were infected with eGFP-Us11 (Patton recombinant strain of HSV-1

expressing an eGFP reporter fused to true late protein Us11). Neurons were infected at

a Multiplicity of Infection (MOI) of 7.5 PFU/cell (assuming $1.0x10^4$ neurons/well/24-well

plate) in DPBS +$CaCl_2$ +$MgCl_2$ supplemented with 1% Fetal Bovine Serum, 4.5 g/L

glucose, and 10 µM Acyclovir (ACV) for three hours at 37 °C. Post-infection, inoculum

was replaced with CM1 containing 50 µM ACV for 5-6 days, followed by CM1 without

ACV. Reactivation was carried out in DMEM/F12 (Gibco) supplemented with 10% Fetal

Bovine Serum, Mouse NGF 2.5S (50 ng/mL) and Primocin. Inhibitors were added either

one hour prior to or concurrently with the reactivation stimulus. WAY-150138 (2-10

µg/mL) was added to reactivation cocktail to limit cell-to-cell spread. Reactivation was

quantified by counting number of GFP-positive neurons or performing Reverse

Transcription Quantitative PCR (RT-qPCR) of HSV-1 lytic mRNAs isolated from the

cells in culture.

Analysis of mRNA expression by reverse-transcription quantitative PCR (RT-

qPCR)

To assess relative expression of HSV-1 lytic mRNA, total RNA was extracted from

approximately 1.0×10^4 neurons using the Quick-RNA™ Miniprep Kit (Zymo Research)

with an on-column DNase I digestion. mRNA was converted to cDNA using the

SuperScript IV First-Strand Synthesis system (Invitrogen) using equal amounts of RNA

(20-30 ng/reaction). To assess viral DNA load, total DNA was extracted from

approximately 1.0×10^4 neurons using the Quick-DNA™ Miniprep Plus Kit (Zymo

Research). qPCR was carried out using *Power* SYBR™ Green PCR Master Mix

(Applied Biosystems). The relative mRNA or DNA copy number was determined using

the Comparative C_T ($\Delta\Delta C_T$) method normalized to mRNA or DNA levels in latently

infected samples. Viral RNAs were normalized to mouse reference gene GAPDH. All

samples were run in duplicate on an Applied Biosystems™ QuantStudio™ 6 Flex Real-

Time PCR System and the mean fold change compared to the reference gene

calculated. Primers used are described in Table S2.

Western Blot Analysis

Neurons were lysed in RIPA Buffer with cOmplete, Mini, EDTA-Free Protease Inhibitor

Cocktail (Roche) and PhosSTOP Phosphatase Inhibitor Cocktail (Roche) on ice for one

hour with regular vortexing to aid lysis. Insoluble proteins were removed via

centrifugation, and lysate protein concentration was determined using the Pierce

Bicinchoninic Acid Protein Assay Kit (Invitrogen) using a standard curve created with

BSA standards of known concentration. Equal quantities of protein (generally 20-50 µg)

were resolved on 4-20% gradient SDS-Polyacrylamide gels (Bio-Rad) and then

transferred onto Polyvinylidene difluoride membranes (Millipore Sigma). Membranes

were blocked in PVDF Blocking Reagent for Can Get Signal (Toyobo) for one hour.

Primary antibodies were diluted in Can Get Signal Immunoreaction Enhancer Solution 1

(Toyobo) and membranes were incubated overnight at 4°C. Antibodies and

concentrations are described in Table S3 below. HRP-labeled secondary antibodies

were diluted in Can Get Signal Immunoreaction Enhancer Solution 2 (Toyobo) and

membranes were incubated for one hour at room temperature. Blots were developed

using Western Lightning Plus-ECL Enhanced Chemiluminescence Substrate

(PerkinElmer) and ProSignal ECL Blotting Film (Prometheus Protein Biology Products)

according to manufacturer's instructions. Blots were stripped for reblotting using

NewBlot PVDF Stripping Buffer (Licor).

Immunofluorescence

Neurons were fixed for 15 minutes in 4% Formaldehyde and blocked in 5% Bovine

Serum Albumin and 0.3% Triton X-100 and incubated overnight in primary antibody.

Antibodies and concentrations are described in Table S4 below. Following primary

antibody treatment, neurons were incubated for one hour in Alexa Fluor® 488-, 555-,

and 647-conjugated secondary antibodies for multi-color imaging (Invitrogen). Nuclei

were stained with Hoechst 33258 (Life Technologies). Images were acquired using an

sCMOS charge-coupled device camera (pco.edge) mounted on a Nikon Eclipse Ti

Inverted Epifluorescent microscope using NIS-Elements software (Nikon). Images were

analyzed and intensity quantified using ImageJ.

Click Chemistry

Click chemistry was carried out a described previously[53] with some modifications.

Neurons were washed with CSK buffer (10 mM HEPES, 100 mM NaCl, 300 mM

Sucrose, 3 mM $MgCl_2$, 5 mM EGTA) and simultaneously fixed and permeabilized for 10

minutes in 1.8% methonal-free formaldehyde (0.5% Triton X-100, 1%

phenylmethylsulfonyl fluoride (PMSF)) in CSK buffer, then washed twice with PBS

before continuing to the click chemistry reaction and immunostaining. Samples were

blocked with 3% BSA for 30 minutes, followed by click chemistry using EdC-labelled

HSV-1 DNA and the Click-iT EdU Alexa Flour 555 Imaging Kit (ThermoFisher Scientific,

C10638) according to the manufacturer's instructions. For immunostaining, samples

were incubated overnight with primary antibodies in 3% BSA. Following primary

antibody treatment, neurons were incubated for one hour in Alexa Fluor® 488-, 555-,

and 647-conjugated secondary antibodies for multi-color imaging (Invitrogen). Nuclei

were stained with Hoechst 33258 (Life Technologies). Images were acquired at 60x

using an sCMOS charge-coupled device camera (pco.edge) mounted on a Nikon

Eclipse Ti Inverted Epifluorescent microscope using NIS-Elements software (Nikon).

Images were analyzed and intensity quantified using ImageJ.

Statistical Analysis

Power analysis was used to determine the appropriate sample sizes for statistical

analysis. All statistical analysis was performed using Prism V8.4. An unpaired t-test was

used for all experiments where the group size was 2. All other experiments were

analyzed using a one-way ANOVA with a Tukey's multiple comparison. Specific

analyses are included in the figure legends. For all reactivation experiments measuring

GFP expression, viral DNA, gene expression or DNA load, individual biological

replicates were plotted (an individual well of primary neurons) and all experiments were

repeated from pools of neurons from at least 3 litters. EdC virus and H3K9me3S10/p

co-localization was quantified using ImageJ after sample blinding of at least 8 fields of

view from 2 biological replicates. Mean fluorescence intensity of γH2AX and

H3K9me3pS10 was quantified using ImageJ from at least 100 cells from at least 3

biological replicates.

References

1   Arvin, A. *et al.* Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis.
(2007).
2   Itzhaki, R. F. Corroboration of a Major Role for Herpes Simplex Virus Type 1 in
Alzheimer's Disease. *Front Aging Neurosci* **10**, 324, doi:10.3389/fnagi.2018.00324 (2018).
3   Suzich, J. B. & Cliffe, A. R. Strength in diversity: Understanding the pathways to herpes
simplex virus reactivation. *Virology* **522**, 81-91, doi:10.1016/j.virol.2018.07.011 (2018).
4   Deshmane, S. L. & Fraser, N. W. During latency, herpes simplex virus type 1 DNA is
associated with nucleosomes in a chromatin structure. *J Virol* **63**, 943-947 (1989).
5   Wang, Q. Y. *et al.* Herpesviral latency-associated transcript gene promotes assembly of
heterochromatin on viral lytic-gene promoters in latent infection. *Proc Natl Acad Sci U S A* **102**,
16055-16059, doi:10.1073/pnas.0505850102 (2005).
6   Knipe, D. M. & Cliffe, A. Chromatin control of herpes simplex virus lytic and latent
infection. *Nat Rev Microbiol* **6**, 211-221, doi:10.1038/nrmicro1794 (2008).
7   Cliffe, A. R., Garber, D. A. & Knipe, D. M. Transcription of the herpes simplex virus
latency-associated transcript promotes the formation of facultative heterochromatin on lytic
promoters. *J Virol* **83**, 8182-8190, doi:10.1128/JVI.00712-09 (2009).
8   Kwiatkowski, D. L., Thompson, H. W. & Bloom, D. C. The polycomb group protein Bmi1
binds to the herpes simplex virus 1 latent genome and maintains repressive histone marks
during latency. *J Virol* **83**, 8173-8181, doi:10.1128/JVI.00686-09 (2009).
9   Wilcox, C. L. & Johnson, E. M., Jr. Characterization of nerve growth factor-dependent
herpes simplex virus latency in neurons in vitro. *J Virol* **62**, 393-399 (1988).
10   Wilcox, C. L., Smith, R. L., Freed, C. R. & Johnson, E. M., Jr. Nerve growth factor-
dependence of herpes simplex virus latency in peripheral sympathetic and sensory neurons in
vitro. *J Neurosci* **10**, 1268-1275 (1990).
11   Camarena, V. *et al.* Nature and duration of growth factor signaling through receptor
tyrosine kinases regulates HSV-1 latency in neurons. *Cell Host Microbe* **8**, 320-330,
doi:10.1016/j.chom.2010.09.007 (2010).
12   Hu, H. L. *et al.* TOP2beta-Dependent Nuclear DNA Damage Shapes Extracellular Growth
Factor Responses via Dynamic AKT Phosphorylation to Control Virus Latency. *Mol Cell* **74**, 466-
480 e464, doi:10.1016/j.molcel.2019.02.032 (2019).
13   Tedeschi, A. & Bradke, F. The DLK signalling pathway--a double-edged sword in neural
development and regeneration. *EMBO reports* **14**, 605-614, doi:10.1038/embor.2013.64 (2013).
14   Geden, M. J. & Deshmukh, M. Axon degeneration: context defines distinct pathways.
Curr Opin Neurobiol **39**, 108-115, doi:10.1016/j.conb.2016.05.002 (2016).
15   Cliffe, A. R. *et al.* Neuronal Stress Pathway Mediating a Histone Methyl/Phospho Switch
Is Required for Herpes Simplex Virus Reactivation. *Cell Host Microbe* **18**, 649-658,
doi:10.1016/j.chom.2015.11.007 (2015).
16   Fischle, W. *et al.* Regulation of HP1–chromatin binding by histone H3 methylation and
phosphorylation. *Nature* **438**, 1116-1122, doi:10.1038/nature04219 (2005).
17   Gehani, S. S. *et al.* Polycomb group protein displacement and gene activation through
MSK-dependent H3K27me3S28 phosphorylation. *Mol Cell* **39**, 886-900,
doi:10.1016/j.molcel.2010.08.020 (2010).

18   Kim, J. Y., Mandarino, A., Chao, M. V., Mohr, I. & Wilson, A. C. Transient reversal of
episome silencing precedes VP16-dependent transcription during reactivation of latent HSV-1 in
neurons. *PLoS Pathog* **8**, e1002540, doi:10.1371/journal.ppat.1002540 (2012).
19   Cliffe, A. R. & Wilson, A. C. Restarting Lytic Gene Transcription at the Onset of Herpes
Simplex Virus Reactivation. *J Virol* **91**, e01419-01416-01416, doi:10.1128/JVI.01419-16 (2017).
20   Liang, Y., Vogel, J. L., Narayanan, A., Peng, H. & Kristie, T. M. Inhibition of the histone
demethylase LSD1 blocks alpha-herpesvirus lytic replication and reactivation from latency. *Nat*
Med **15**, 1312-1317, doi:10.1038/nm.2051 (2009).
21   Liang, Y. *et al.* Targeting the JMJD2 histone demethylases to epigenetically control
herpesvirus infection and reactivation from latency. *Sci Transl Med* **5**, 167ra165,
doi:10.1126/scitranslmed.3005145 (2013).
22   Messer, H. G., Jacobs, D., Dhummakupt, A. & Bloom, D. C. Inhibition of H3K27me3-
specific histone demethylases JMJD3 and UTX blocks reactivation of herpes simplex virus 1 in
trigeminal ganglion neurons. *J Virol* **89**, 3417-3420, doi:10.1128/JVI.03052-14 (2015).
23   Hill, J. M. *et al.* Inhibition of LSD1 reduces herpesvirus infection, shedding, and
recurrence by promoting epigenetic suppression of viral genomes. *Sci Transl Med* **6**, 265ra169,
doi:10.1126/scitranslmed.3010643 (2014).
24   Noh, K. M. *et al.* ATRX tolerates activity-dependent histone H3 methyl/phos switching to
maintain repetitive element silencing in neurons. *Proc Natl Acad Sci U S A* **112**, 6820-6827,
doi:10.1073/pnas.1411258112 (2015).
25   Smith, R. L., Pizer, L. I., Johnson, E. M., Jr. & Wilcox, C. L. Activation of second-messenger
pathways reactivates latent herpes simplex virus in neuronal cultures. *Virology* **188**, 311-318,
doi:10.1016/0042-6822(92)90760-m (1992).
26   Colgin, M. A., Smith, R. L. & Wilcox, C. L. Inducible cyclic AMP early repressor produces
reactivation of latent herpes simplex virus type 1 in neurons in vitro. *J Virol* **75**, 2912-2920,
doi:10.1128/JVI.75.6.2912-2920.2001 (2001).
27   De Regge, N., Van Opdenbosch, N., Nauwynck, H. J., Efstathiou, S. & Favoreel, H. W.
Interferon Alpha Induces Establishment of Alphaherpesvirus Latency in Sensory Neurons In
Vitro. *PLoS ONE* **5**, e13076, doi:10.1371/journal.pone.0013076.t001 (2010).
28   Danaher, R. J., Jacob, R. J. & Miller, C. S. Herpesvirus quiescence in neuronal cells. V:
forskolin-responsiveness of the herpes simplex virus type 1 alpha0 promoter and contribution
of the putative cAMP response element. *J Neurovirol* **9**, 489-497,
doi:10.1080/13550280390218797 (2003).
29   Alt, F. W. & Schwer, B. DNA double-strand breaks as drivers of neural genomic change,
function, and disease. *DNA Repair (Amst)* **71**, 158-163, doi:10.1016/j.dnarep.2018.08.019
(2018).
30   Madabhushi, R. *et al.* Activity-Induced DNA Breaks Govern the Expression of Neuronal
Early-Response Genes. *Cell* **161**, 1592-1605, doi:10.1016/j.cell.2015.05.032 (2015).
31   Ericsson, A., Kovacs, K. J. & Sawchenko, P. E. A functional anatomical analysis of central
pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. *J*
Neurosci **14**, 897-913, doi:10.1523/jneurosci.14-02-00897.1994 (1994).
32   Goshen, I. & Yirmiya, R. Interleukin-1 (IL-1): a central regulator of stress responses. *Front*
Neuroendocrinol **30**, 30-45, doi:10.1016/j.yfrne.2008.10.001 (2009).

33   Koo, J. W. & Duman, R. S. Interleukin-1 receptor null mutant mice show decreased
anxiety-like behavior and enhanced fear memory. *Neurosci Lett* **456**, 39-43,
doi:10.1016/j.neulet.2009.03.068 (2009).
34   Saper, C. B. & Breder, C. D. The neurologic basis of fever. *N Engl J Med* **330**, 1880-1886,
doi:10.1056/NEJM199406303302609 (1994).
35   Glaser, R. & Kiecolt-Glaser, J. K. Chronic stress modulates the virus-specific immune
response to latent herpes simplex virus type 1. *Ann Behav Med* **19**, 78-82,
doi:10.1007/BF02883323 (1997).
36   Cohen, F. *et al.* Persistent stress as a predictor of genital herpes recurrence. *Arch Intern*
Med **159**, 2430-2436, doi:10.1001/archinte.159.20.2430 (1999).
37   Chida, Y. & Mao, X. Does psychosocial stress predict symptomatic herpes simplex virus
recurrence? A meta-analytic investigation on prospective studies. *Brain, behavior, and*
immunity **23**, 917-925, doi:10.1016/j.bbi.2009.04.009 (2009).
38   Vezzani, A. & Viviani, B. Neuromodulatory properties of inflammatory cytokines and
their impact on neuronal excitability. *Neuropharmacology* **96**, 70-82,
doi:10.1016/j.neuropharm.2014.10.027 (2015).
39   Schneider, H. *et al.* A neuromodulatory role of interleukin-1beta in the hippocampus.
Proc Natl Acad Sci U S A **95**, 7778-7783, doi:10.1073/pnas.95.13.7778 (1998).
40   Binshtok, A. M. *et al.* Nociceptors are interleukin-1beta sensors. *J Neurosci* **28**, 14062-
14073, doi:10.1523/JNEUROSCI.3795-08.2008 (2008).
41   Orzalli, M. H. *et al.* An Antiviral Branch of the IL-1 Signaling Pathway Restricts Immune-
Evasive Virus Replication. *Mol Cell* **71**, 825-840 e826, doi:10.1016/j.molcel.2018.07.009 (2018).
42   Aarreberg, L. D. *et al.* Interleukin-1beta Induces mtDNA Release to Activate Innate
Immune Signaling via cGAS-STING. *Mol Cell* **74**, 801-815 e806,
doi:10.1016/j.molcel.2019.02.038 (2019).
43   Benboudjema, L., Mulvey, M., Gao, Y., Pimplikar, S. W. & Mohr, I. Association of the
herpes simplex virus type 1 Us11 gene product with the cellular kinesin light-chain-related
protein PAT1 results in the redistribution of both polypeptides. *J Virol* **77**, 9192-9203,
doi:10.1128/jvi.77.17.9192-9203.2003 (2003).
44   Hoshi, T., Garber, S. S. & Aldrich, R. W. Effect of forskolin on voltage-gated K+ channels
is independent of adenylate cyclase activation. *Science* **240**, 1652-1655 (1988).
45   Kandel, E. R. The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and
CPEB. *Mol Brain* **5**, 14, doi:10.1186/1756-6606-5-14 (2012).
46   de Rooij, J. *et al.* Mechanism of regulation of the Epac family of cAMP-dependent
RapGEFs. *J Biol Chem* **275**, 20829-20836, doi:10.1074/jbc.M001113200 (2000).
47   Gandia, L. *et al.* Differential effects of forskolin and 1,9-dideoxy-forskolin on nicotinic
receptor- and K+-induced responses in chromaffin cells. *Eur J Pharmacol* **329**, 189-199 (1997).
48   Haslam, R. J., Davidson, M. M. & Desjardins, J. V. Inhibition of adenylate cyclase by
adenosine analogues in preparations of broken and intact human platelets. Evidence for the
unidirectional control of platelet function by cyclic AMP. *Biochem J* **176**, 83-95,
doi:10.1042/bj1760083 (1978).
49   Patel, S. *et al.* Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with
activity in neurodegeneration models. *J Med Chem* **58**, 401-418, doi:10.1021/jm5013984
(2015).

50   van Zeijl, M. *et al.* Novel class of thiourea compounds that inhibit herpes simplex virus
type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene. *J Virol* **74**, 9054-9061,
doi:10.1128/jvi.74.19.9054-9061.2000 (2000).

51   Newcomb, W. W. & Brown, J. C. Inhibition of herpes simplex virus replication by WAY-
150138: assembly of capsids depleted of the portal and terminase proteins involved in DNA
encapsidation. *J Virol* **76**, 10084-10088, doi:10.1128/jvi.76.19.10084-10088.2002 (2002).

52   Hao, Y. *et al.* An evolutionarily conserved mechanism for cAMP elicited axonal
regeneration involves direct activation of the dual leucine zipper kinase DLK. *eLife* **5**, e14048,
doi:10.7554/eLife.14048 (2016).

53   Alandijany, T. *et al.* Distinct temporal roles for the promyelocytic leukaemia (PML)
protein in the sequential regulation of intracellular host immunity to HSV-1 infection. *PLoS*
Pathog **14**, e1006769, doi:10.1371/journal.ppat.1006769 (2018).

54   McFarlane, S. *et al.* The histone chaperone HIRA promotes the induction of host innate
immune defences in response to HSV-1 infection. *PLoS Pathog* **15**, e1007667,
doi:10.1371/journal.ppat.1007667 (2019).

55   Kruidenier, L. *et al.* A selective jumonji H3K27 demethylase inhibitor modulates the
proinflammatory macrophage response. *Nature* **488**, 404-408, doi:10.1038/nature11262
(2012).

56   Sartiani, L., Mannaioni, G., Masi, A., Novella Romanelli, M. & Cerbai, E. The
Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels: from Biophysics to
Pharmacology of a Unique Family of Ion Channels. *Pharmacol Rev* **69**, 354-395,
doi:10.1124/pr.117.014035 (2017).

57   Kullmann, P. H. *et al.* HCN hyperpolarization-activated cation channels strengthen
virtual nicotinic EPSPs and thereby elevate synaptic amplification in rat sympathetic neurons. *J*
Neurophysiol **116**, 438-447, doi:10.1152/jn.00223.2016 (2016).

58   DiFrancesco, D. & Tortora, P. Direct activation of cardiac pacemaker channels by
intracellular cyclic AMP. *Nature* **351**, 145-147, doi:10.1038/351145a0 (1991).

59   Kase, D. & Imoto, K. The Role of HCN Channels on Membrane Excitability in the Nervous
System. *J Signal Transduct* **2012**, 619747, doi:10.1155/2012/619747 (2012).

60   Ibata, K., Sun, Q. & Turrigiano, G. G. Rapid synaptic scaling induced by changes in
postsynaptic firing. *Neuron* **57**, 819-826, doi:10.1016/j.neuron.2008.02.031 (2008).

61   Turrigiano, G. G., Leslie, K. R., Desai, N. S., Rutherford, L. C. & Nelson, S. B. Activity-
dependent scaling of quantal amplitude in neocortical neurons. *Nature* **391**, 892-896,
doi:10.1038/36103 (1998).

62   Lee, H. K. & Kirkwood, A. Mechanisms of Homeostatic Synaptic Plasticity in vivo. *Front*
Cell Neurosci **13**, 520, doi:10.3389/fncel.2019.00520 (2019).

63   Sokolova, I. V. & Mody, I. Silencing-induced metaplasticity in hippocampal cultured
neurons. *J Neurophysiol* **100**, 690-697, doi:10.1152/jn.90378.2008 (2008).

64   Emery, E. C., Young, G. T., Berrocoso, E. M., Chen, L. & McNaughton, P. A. HCN2 ion
channels play a central role in inflammatory and neuropathic pain. *Science* **333**, 1462-1466,
doi:10.1126/science.1206243 (2011).

65   Doll, J. R., Hoebe, K., Thompson, R. L. & Sawtell, N. M. Resolution of herpes simplex virus
reactivation in vivo results in neuronal destruction. *PLoS Pathog* **16**, e1008296,
doi:10.1371/journal.ppat.1008296 (2020).

66   Koyuncu, O. O., MacGibeny, M. A., Hogue, I. B. & Enquist, L. W. Compartmented
neuronal cultures reveal two distinct mechanisms for alpha herpesvirus escape from genome
silencing. *PLoS Pathog* **13**, e1006608, doi:10.1371/journal.ppat.1006608 (2017).
67   Xie, F. *et al.* Identification of a Potent Inhibitor of CREB-Mediated Gene Transcription
with Efficacious in Vivo Anticancer Activity. *J Med Chem* **58**, 5075-5087,
doi:10.1021/acs.jmedchem.5b00468 (2015).
68   Riccio, A., Ahn, S., Davenport, C. M., Blendy, J. A. & Ginty, D. D. Mediation by a CREB
family transcription factor of NGF-dependent survival of sympathetic neurons. *Science* **286**,
2358-2361 (1999).
69   Weber, A., Wasiliew, P. & Kracht, M. Interleukin-1 (IL-1) pathway. *Sci Signal* **3**, cm1,
doi:10.1126/scisignal.3105cm1 (2010).
70   Listwak, S. J., Rathore, P. & Herkenham, M. Minimal NF-kappaB activity in neurons.
Neuroscience **250**, 282-299, doi:10.1016/j.neuroscience.2013.07.013 (2013).
71   Kaltschmidt, B. & Kaltschmidt, C. NF-kappaB in the nervous system. *Cold Spring Harb*
Perspect Biol **1**, a001271, doi:10.1101/cshperspect.a001271 (2009).
72   Yeh, J. X., Park, E., Schultz, K. L. W. & Griffin, D. E. NF-kappaB Activation Promotes
Alphavirus Replication in Mature Neurons. *J Virol* **93**, e01071-01019, doi:10.1128/JVI.01071-19
(2019).
73   Qian, J. *et al.* Interleukin-1R3 mediates interleukin-1-induced potassium current increase
through fast activation of Akt kinase. *Proc Natl Acad Sci U S A* **109**, 12189-12194,
doi:10.1073/pnas.1205207109 (2012).
74   Srinivasan, D., Yen, J. H., Joseph, D. J. & Friedman, W. Cell type-specific interleukin-1beta
signaling in the CNS. *J Neurosci* **24**, 6482-6488, doi:10.1523/JNEUROSCI.5712-03.2004 (2004).
75   Mrak, R. E. & Griffin, W. S. Interleukin-1, neuroinflammation, and Alzheimer's disease.
Neurobiol Aging **22**, 903-908, doi:10.1016/s0197-4580(01)00287-1 (2001).
76   Wu, C. C. *et al.* Akt suppresses DLK for maintaining self-renewal of mouse embryonic
stem cells. *Cell Cycle* **14**, 1207-1217, doi:10.1080/15384101.2015.1014144 (2015).

894 <u>Supplemental Materials and Methods Tables</u>
895

896 Table S1: Compounds Used and Concentrations

Compound	Supplier	Identifier	Concentration
Acycloguanosine	Millipore Sigma	A4669	10 µM, 50 µM
FUDR	Millipore Sigma	F-0503	20 µM
Uridine	Millipore Sigma	U-3003	20 µM
SP600125	Millipore Sigma	S5567	20 µM
GNE-3511	Millipore Sigma	533168	4 µM
GSK-J4	Millipore Sigma	SML0701	2 µM
L-Glutamic Acid	Millipore Sigma	G5638	3.7 µg/mL
Forskolin	Tocris	1099	60 µM
LY 294002	Tocris	1130	20 µM
666-15	Tocris	5661	2 µM
SQ 22,536	Tocris	1435	50 µM
KT 5720	Tocris	1288	3 µM
TEA	Tocris	3068	10 mM
CsCl	Tocris	4739	3 mM
OG-L002	Tocris	6244	15 µM, 30 µM
S2101	Tocris	5714	10 µM, 20 µM
Tetrodotoxin	Tocris	1069	1 µM
ESI-09	Tocris	4773	10 µM
ZD 7288	Cayman	15228	20 µM

8-bromo-cyclic AMP	Cayman	14431	125 µM
NGF 2.5S	Alomone Labs	N-100	50 ng/mL
Primocin	Invivogen	ant-pm-1	100 µg/mL
Aphidicolin	AG Scientific	A-1026	3.3 µg/mL
IL-1β	Shenandoah Bio.	100-167	30ng/mL
WAY-150138	Pfizer	NA	10 µg/mL

900   Table S2: Primers Used for RT-qPCR

Primer	Sequence 5' to 3'
mGAP 1SF	CAT GGC CTT CCG TGT GTT CCT A
mGAP 1SR	GCG GCA CGT CAG ATC CA
ICP27 F	GCA TCC TTC GTG TTT GTC ATT CTG
ICP27 R	GCA TCT TCT CTC CGA CCC CG
ICP8 1SF	GGA GGT GCA CCG CAT ACC
ICP8 1SR	GGC TAA AAT CCG GCA TGA AC
ICP4 F	TGC TGC TGC TGT CCA CGC
ICP4 R	CGG TGT TGA CCA CGA TGA GCC
UL30 F	CGC GCT TGG CGG GTA TTA ACA T
UL30 R	TGG GTG TCC GGC AGA ATA AAG C
UL48 F	TGC TCG CGA ATG TGG TTT AG
UL48 R	CTG TTC AGC CCT TCA TGT TT
gC #1 F	GAG TTT GTC TGG TTC GAG GAC
gC #1R	ACG GTA GAG ACT GTG GTG AA

906   Table S3: Antibodies Used for Western Blotting and Concentrations

Antibody	Supplier	Identifier	Concentration
Rb Phospho-Akt (S473)	CST	4060	1:500
Rb Akt (pan)	CST	C67E7	1:1000
Rb Phospho-c-Jun (S73)	CST	3270	1:500
Ms Monoclonal α-Tubulin	Millipore Sigma	T9026	1:2500
HRP Goat Anti-Rabbit IgG Antibody (Peroxidase)	Vector	PI-1000	1:10000
HRP Horse Anti-Mouse IgG Antibody (Peroxidase)	Vector	PI-2000	1:10000

910   Table S4: Antibodies Used for Immunofluorescence and Concentrations

Antibody	Supplier	Identifier	Concentration
Rb H3K9me3S10P	Abcam	ab5819	1:250
Ch Beta-III Tubulin	Millipore sigma	AB9354	1:1000
Ms γH2A.X	CST	80312S	1:100
Ms c-Fos	Novus	NB110-75039	1:125
F(ab')2 Goat anti Mouse IgG (H+L) Alexa Fluor® 647	Thermo Fisher	A21237	1:1000
F(ab') Goat anti Rabbit IgG (H+L) Alexa Fluor® 555	Thermo Fisher	A21425	1:1000
Goat anti Chicken IgY (H+L) Alexa Fluor® 647	abcam	ab150175	1:1000
Goat Anti-Chicken IgY H&L (Alexa Fluor® 488) preabsorbed	abcam	ab150173	1:1000
F(ab')2 Goat anti-Rabbit IgG (H+L) Alexa Fluor® 488)	Thermo Fisher	B40922	1:1000

914   Table S5: Cell Body Score for Neuronal Health and Degeneration Index

Score	Description
0	Large, phase bright cell bodies. Clear with no fragmentation or vesiculation.
1	Small, phase bright cell bodies. Clear with no fragmentation or vesiculation.
2	Cell bodies do not have fragmentation but are not phase bright. Sometimes appear transparent.
3	Cell bodies with fragmentation but few dead neurons or corpses.
4	Cell bodies with fragmentation with many corpses present and neurons starting to detach.
5	Complete cell death. Neurons detached.

916   Table S6: Axon Score for Neuronal Health and Degeneration Index

Score	Description
0	Axons totally smooth with no blebbing or fragmentation. Branched and form a spider web-like network.
1	Axons smooth but grow straight.
2	Blebbing on the axons but no apparent fragmentation.
3	Fragmentation starting to appear in <50% of the neurons.
4	Fragmentation in >50% of the neurons.
5	No axons remaining.

921
922